EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Statin therapy and the risk of rhabdomyolysis in hypercholesterolemic populations

Hanifah Fazilatun Nisa, Syahrul Tuba

Lentera Negeri · 02.10.2026 · 7 (1) · 1966-1973

DOI: 10.29210/993720 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lentera Negeri, online erschienen am 02.10.2026. Verfasst von Hanifah Fazilatun Nisa und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Statins remain the gold-standard pharmacologic therapy for hypercholesterolemia, but their use is occasionally limited by statin-associated muscle symptoms (SAMS), of which rhabdomyolysis is the most severe form (Dicken et al., 2022; Safitri et al., 2021). To systematically synthesize evidence published between 2010 and 2025 on the incidence, molecular mechanisms, genetic determinants, and preventive management of statin-induced rhabdomyolysis in hypercholesterolemic populations, and to identify what current evidence still leaves unresolved. A narrative literature review was conducted using Google Scholar and PubMed with the Boolean strategy ("statin*" OR "HMG-CoA reductase inhibitor*") AND ("rhabdomyolysis" OR "myopathy" OR "statin-associated muscle symptoms") AND "hypercholesterolemia". Screening followed a three-stage PRISMA-style process (identification, title/abstract screening, full-text eligibility), and included studies were appraised narratively for design, sample size, and completeness of reported outcomes, prioritizing peer-reviewed sources indexed in Scopus or Sinta and published in 2021-2025, while retaining seminal 2010-2018 randomized trials as primary sources of the quantitative incidence data. Six primary clinical studies (n = 24 to 584,784) reported rhabdomyolysis incidences ranging from 0.003% with statin monotherapy to 4.17% under high-dose oncology co-administration; risk rose sharply with fibrate co-therapy (particularly gemfibrozil), high-dose or lipophilic statins, and loss-of-function SLCO1B1 variants (Turongkaravee et al., 2021). Rhabdomyolysis attributable to statin monotherapy is rare (generally

Zitieren

APA

Nisa, H. F., & Tuba, S. (2026). Statin therapy and the risk of rhabdomyolysis in hypercholesterolemic populations. Lentera Negeri, 7(1), 1966-1973. https://doi.org/10.29210/993720

Vancouver

Nisa HF, Tuba S. Statin therapy and the risk of rhabdomyolysis in hypercholesterolemic populations. Lentera Negeri. 2026;7(1):1966-1973. doi:10.29210/993720

BibTeX
@article{Nisa2026,
  author = {Nisa, Hanifah Fazilatun and Tuba, Syahrul},
  title = {Statin therapy and the risk of rhabdomyolysis in hypercholesterolemic populations},
  journal = {Lentera Negeri},
  year = {2026},
  volume = {7},
  number = {1},
  pages = {1966--1973},
  doi = {10.29210/993720}
}
Kostenlos starten →